Antileishmanial activities and mechanisms of action of indole-based azoles

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 21, Issue 3, 2006, Pages 277-283

  Pagniez, Fabrice ^a   Abdala Valencia, Hiam ^a   Marchand, Pascal ^a   Le Borgne, Marc ^a   Le Baut, Guillaume ^a   Robert Piessard, Sylvie ^a   Le Pape, Patrice ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Antileishmanials; Azole derivatives; Ergosterol; Interleukine 4; Leishmania

Indexed keywords

3 (ALPHA AZOLYLBENZYL)INDOLE DERIVATIVE; 5 BROMO 3 [(2,4 DICHLOROPHENYL)(1H IMIDAZOL 1 YL)METHYL] 1 ETHYLINDOLE; ANTILEISHMANIAL AGENT; ANTIPROTOZOAL AGENT; ERGOSTEROL; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INTERLEUKIN 4; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PHOSPHOLIPASE A2; PM 17; PM 19; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FUNGAL CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PARASITE LOCALIZATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; STEROL SYNTHESIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; ANTIPROTOZOAL AGENTS; AZOLES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOSTEROL; IMIDAZOLES; INDOLES; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PHOSPHOLIPASES A; SENSITIVITY AND SPECIFICITY; SPLEEN; TRIAZOLES;

LEISHMANIA MAJOR; LEISHMANIA MEXICANA;

EID: 33746174190     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360600700517     Document Type: Article

References (26)

1. Berman, JD. (1997) Clin Infect Dis, 24, pp. 684-703.
2. Davidson, RN and Croft, SL. (1993) Trans R Soc Trop Med Hyg, 87, pp. 130.
3. Raffi, F and Merrien, D and Le Pape, P and Reliquet, V. (1995) Clin Infect Dis, 21, pp. 1338-1339.
4. Navin, TR and Arana, BA and Arana, FE and Berman, JD and Chajon, JF. (1992) J Infect Dis, 165, pp. 528-534.
5. Weinrauch, L and Livishin, R and Evan-Paz, Z and El-On, J. (1983) Arch Dermatol Res, 275, pp. 353-354.
6. Berman, JD. (1988) Rev Infect Dis, 10, pp. 560-586.
7. Hitchcock, CA. (1991) Biochem Soc Trans, 19, pp. 782-787.
8. Abdala, H and Robert, JM and Le Pape, P and Wielgosz, G and Robert-Piessard, S and Le Baut, G. (2000) Arzn-Forsch/Drug Res, 50, pp. 479-484.
9. Dillard, RD and Bach, NJ and Draheim, SE and Berry, DR and Carlson, DG and Chirgadze, NY and Clawson, DK and Hartley, LW and Johnson, LM and Jones, ND and McKinney, ER and Mihelich, ED and Olkowski, JL and Schevitz, RW and Smith, AC and Snyder, DW and Sommers, CD and Wery, JP. (1996) J Med Chem, 39, pp. 5119-5136.
10. Schevitz, RW and Bach, NJ and Carlson, DG and Chirgadze, NY and Clawson, DK and Dillard, RD and Draheim, SE and Hartley, LW and Jones, ND and Mihelich, ED and Olkowski, JL and Snyder, DW and Sommers, C and Wery, JP. (1995) Nat Struct Biol, 2, pp. 458-465.
11. Mattner, F and Di Padova, K and Alber, G. (1997) Infect Immun, 65, pp. 4378-4383.
12. Lucey, DR and Clerici, M and Shearer, GM. (1996) Clin Microbiol Rev, 9, pp. 532-562.
13. Falcoff, E and Taranto, NJ and Remondegui, CE and Dedet, JP and Canini, LM and Ripoll, CM and Dimier-David, L and Vargas, F and Gimenez, LA and Bernabo, JG. (1994) Trans R Soc Trop Med Hyg, 88, pp. 95-97.
14. Cenci, E and Mencacci, A and Del Sero, G and Bistoni, F and Romani, L. (1997) J Infect Dis, 176, pp. 217-226.
15. Pagniez, F and Le Pape, P. (2001) J Mycol Médic, 11, pp. 73-78.
16. Croft, SL and Neal, RA and Herrmann, D.B.J. (1993) Trans R Soc Trop Med Hyg, 87, pp. 217-219.
17. Le Pape, P and Abdala, H and Pagniez, F and Robert, JM and Le Baut, G. (1999) Acta Parasitol, 44, pp. 156-159.
18. Arthington-Skaggs, BA and Warnock, DW and Morrison, CJ. (2000) Antimicrob Agents Chemother, 44, pp. 2081-2085.
19. Le Pape, P and Zidane, M and Abdala, H and More, MT. (2000) Cell Biol Int, 1, pp. 51-56.
20. Gasser, RA Jr and Magill, AJ and Oster, CN and Franke, ED and Grogl, M and Berman, JD. (1994) Clin Infect Dis, 18, pp. 83-90.
21. Al-Abdely, HM and Graybill, JR and Loebenberg, D and Melby, PC. (1999) Antimicrob Agents Chemother, 43, pp. 2904-2910.
22. Bastide, M and Mallie, M and Jouvert, S and Montes, B and Bastide, JM. (1989) Pathol Biol, 37, pp. 694-989.
23. Mallie, M and Jouvert, S and Batide, M and Montes, B and Lebecq, JC and Bastide, JM. (1988) Pathol Biol, 36, pp. 575-580.
24. Ghannoum, MA and Rice, LB. (1999) Clin Microbiol Rev, 12, pp. 501-517.
25. Alvarez C, Alvarez N, Pagniez F, Abdala H, Le Pape P. Evaluation of an IL-4 inhibitor in the treatment of leishmaniasis XVth International Congress for Tropical Medicine and Malaria; 2000 Aug 20-25; Carthagena, Colombia.
26. Jankovic, D and Liu, Z and Gause, WC. (2001) Trends Immunol, 22, pp. 450-457.